Simulations Plus, Inc. (SLP)
| Market Cap | 893.47M |
| Revenue (ttm) | 59.58M |
| Net Income (ttm) | 9.96M |
| Shares Out | 19.97M |
| EPS (ttm) | 0.49 |
| PE Ratio | 91.33 |
| Forward PE | 66.46 |
| Dividend | $0.24 (0.54%) |
| Ex-Dividend Date | Oct 27, 2023 |
| Volume | 101,738 |
| Open | 45.62 |
| Previous Close | 45.65 |
| Day's Range | 44.60 - 45.66 |
| 52-Week Range | 32.58 - 52.69 |
| Beta | 0.63 |
| Analysts | Strong Buy |
| Price Target | 61.00 (+36.31%) |
| Earnings Date | Jan 3, 2024 |
About SLP
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as... [Read more]
Financial Performance
In 2023, SLP's revenue was $59.58 million, an increase of 10.52% compared to the previous year's $53.91 million. Earnings were $9.96 million, a decrease of -20.20%.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for SLP stock is "Strong Buy." The 12-month stock price forecast is $61.0, which is an increase of 36.31% from the latest price.
News
Simulations Plus Announces First Quarter Fiscal Year 2024 Earnings and Conference Call Date
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report first quarter fiscal 2024 financial results after the market close on...
Simulations Plus Outlines Paths to Win at 2023 Investor Day
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a virtual investor day today, Nov. 14, 2023, starting at 1:00 pm ET, with presentations by the Company's leadership team.
Simulations Plus to Host Investor Day on Tuesday, November 14th
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, and the leadership team will participate in the Company's virtual Investor Day on Tuesday, Nov 14, at 1 p.m. ET.
Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Results
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported financial results for the 4th quarter and full fiscal year 2023. Total FY23 revenue increased 11% to $59.6 million.
Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a conference call & webcast on October 25, 2023, at 5pm ET to discuss 4th quarter & fiscal year 2023 financial results.
Simulations Plus Receives New FDA Grant Award
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus was awarded a new funded grant from the U.S. FDA to validate best practices for PBBM/PBPK modeling workflows to simulate VBE studies.
Simulations Plus Hosts First-of-its-Kind Virtual Summer Camp for Students and Professors
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus hosted its first University+ PBPK Summer Camp, an intensive 8-week PBPK modeling course for more than 80 attendees from 26 countries.
Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)
LANCASTER, Calif.--(BUSINESS WIRE)--Dr. Viera Lukacova, Chief Science Officer of Simulations Plus, was selected to be a Fellow of the American Association of Pharmaceutical Scientists.
Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment
LANCASTER, Calif.--(BUSINESS WIRE)--The July 2023 issue of Clinical Pharmacology & Therapeutics published research where DILIsym was used to predict liver safety of CBD & VPA treatments.
Simulations Plus Releases ADMET Predictor® 11
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the release of ADMET Predictor 11 with significant enhancements expressly designed to accelerate drug discovery research.
Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported revenue growth in the 3rd quarter of FY23 with 3Q revenue up 9% to $16.2 million; 9mo revenue up 4% to $43.9 million.
Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a conference call and webcast on July 6, 2023, at 5pm EDT to discuss the financial results from the 3rd quarter of FY2023.
Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today the acquisition of Immunetrics, Inc., an addition of important and proven QSP technology in new therapeutic areas.
Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today the release of a targeted package of software and services for accelerating pulmonary drug discovery and development.
Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the US FDA renewed licenses to DILIsym, its flagship QST software, ensuring the agency's continued access for another year.
Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reported revenue growth in the 2nd quarter of FY23 with total 2Q revenue up 6% to $15.8 million; YTD revenue up 2% to $27.7 million.
Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus collaborates with the Sino-American Cancer Foundation to use its AIDD technology & expertise to discover new anticancer therapies.
Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference Call
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a webcast & conference call on April 5, 2023, at 5pm EDT to discuss the financial results from the 2nd quarter of FY2023.
Simulations Plus to Present at Sidoti March Small-Cap Conference
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced th...
Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, using its AI/ML technologies in ADMET Predictor, will partner with the Polish Academy of Sciences to design novel lead molecules.
Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced th...
Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced th...
Simulations Plus and Global Agrochemicals Leader to Collaborate on Machine Learning Models
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced it...
Simulations Plus Releases Redesigned NAFLDsym® QSP Software Tool
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced the release of NAFLDsym v2B Beta, its QSP software tool redesigned to be faster, more intuitive, and more flexible.
Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced ...